CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Trial Details

NCT ID
NCT05722418
Phase
PHASE1
Sponsor
Caribou Biosciences, Inc.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • CB-011
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Miami, Florida, United States|25.77427,-80.19366
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)
  • Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an ant…
  • Eastern Cooperative Oncology Group performance status grade of 0 or 1.
  • Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →